NKGen Biotech will present its lead investigational program, Troculeucel, at the BIOCHINA Global Forum in Seoul on 10 July 2026.
The company’s chairman and chief executive officer, Paul Y. Song, M.D., is scheduled to speak 10 July at 13:40–14:00 KST (12:40–1:00 AM ET) on the use of Troculeucel, described by the company as a cryopreserved enhanced autologous natural killer cell therapy, for neurodegenerative diseases.
According to the company, Troculeucel is currently being evaluated in a Phase 2 clinical trial for Alzheimer’s disease, and the company is exploring applications in amyotrophic lateral sclerosis, frontotemporal dementia, and Parkinson’s disease.
The presentation will also address the regulatory environment in China and select free trade zones that the company says may support development and potential commercialization and partnerships with Chinese pharmaceutical firms and CDMOs.
The World Health Organization has assigned the international nonproprietary name Troculeucel to SNK01 and this is a step toward commercialization.
A copy of the presentation will be posted on the company’s Scientific Publications page after the event, according to the company.
